Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
Pharma News, 2021
New machine learning method enhances computational prediction of RNA structures
Researchers present ARES (Atomic Rotationally Equivariant Scorer) – a machine learning method that significantly improves the computational prediction of RNA structures over previous approac...
BioMarin climbs as dwarfism drug improves growth in children
Aug 27.
NICE ‘no’ for Janssen’s Darzalex combo
The National Institute for Health and Care Excellence (NICE) has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, thalido...
MSD’s pneumococcal vaccine hits ‘key endpoints’ in Phase III
Topline results from the PNEU-PED study evaluating MSD’s pneumococcal vaccine Vaxneuvance in healthy infants between 42-90 days of age have shown a “statistically superior” immune response compa...
Cara, Vifor receive FDA nod for pruritus treatment
Vifor Pharma and Cara Therapeutics’ Korsuva injection has been approved by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic ...
European Commission approves AbbVie’s Rinvoq for atopic dermatitis
The European Commission (EC) has approved AbbVie's Rinvoq (upadacitinib) to treat moderate to severe atopic dermatitis in adults and adolescents aged 12 years and above who are can...
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif.
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
Novartis has reported that Kymriah (tisagenlecleucel) failed to meet the primary goal of the Phase III BELINDA clinical trial in aggressive B-cell non-Hodgkin lymphoma (NHL) patients w...
Theravance’s izencitinib fails in Phase IIb ulcerative colitis trial
Theravance Biopharma has reported that its drug candidate izencitinib (TD-1473) failed to meet the primary endpoint in Phase IIb dose-finding induction clinical trial to treat ulcerative colit...
U.S. could control COVID by spring 2022 if more people get shots - Fauci
WASHINGTON, Aug 24 (Reuters) - The United States could get COVID-19 under control by early next year if vaccinations ramp up, Dr.
Merck KGaA, GSK's bintrafusp alfa chalks up another loss in biliary tract cancer
Merck KGaA said Monday it has decided to pull the plug on a Phase II study evaluating bintrafusp alfa as a potential treatment for patients with locally advanced or metastatic biliary tract cancer ...
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
MELBOURNE, Australia, Aug.
20
21
22
23
24
25
26
27
28
